文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

单剂阿德西珠单抗对比安慰剂治疗急性心源性休克(ACCOST-HH):一项研究者发起的随机双盲安慰剂对照多中心试验

Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial.
PubMed 文献 · Lancet Respir Med · 2021-12-08
一句话结论在急性心源性休克患者中,单剂阿德西珠单抗(8 mg/kg)耐受性良好,但未减少心血管器官支持需求,也未改善30天和90天生存率。

ACCOST-HH是一项在德国4所大学医院开展的研究者发起、随机、双盲、安慰剂对照、多中心试验,纳入150例心源性休克患者,按1:1随机接受静脉阿德西珠单抗(8 mg/kg体重)或安慰剂。主要终点为30天内无需心血管器官支持(血管升压药、正性肌力药或机械循环支持)的天数,阿德西珠单抗组12.37天(95%CI 9.80-14.94)vs 安慰剂组14.05天(95%CI 11.41-16.69),调整后平均差-1.69天(95%CI -5.37至2.00),p=0.37。严重不良事件两组相似(59例 vs 57例,OR 0.92,95%CI 0.43-1.98,p=0.83);30天死亡率(HR 0.99,95%CI 0.60-1.65,p=0.98)和90天死亡率(HR 1.10,95%CI 0.68-1.77,p=0.71)均无差异。作者结论认为阿德西珠单抗耐受性良好,但未减少心血管器官支持需求或改善生存。

要点

  • 在急性心源性休克患者中,单剂静脉阿德西珠单抗8 mg/kg未减少30天内无需心血管器官支持的天数:12.37天 vs 14.05天,调整后平均差-1.69天(95%CI -5.37至2.00),p=0.37。
  • 30天死亡率两组无差异:HR 0.99(95%CI 0.60-1.65),p=0.98;90天死亡率亦无差异:HR 1.10(95%CI 0.68-1.77),p=0.71。
  • 严重不良事件发生率两组相似:阿德西珠单抗组59例 vs 安慰剂组57例,OR 0.92(95%CI 0.43-1.98),p=0.83。
  • 阿德西珠单抗在急性心源性休克患者中耐受性良好,但未改善主要终点或生存率。

适用人群与场景

  • 年龄18岁及以上、因心源性休克住院且在过去48小时内的患者。
  • 排除:复苏时间超过60分钟者;由持续性室性心动过速或心动过缓导致的心源性休克患者。
  • 研究在德国4所大学医院开展,患者为成人心源性休克住院患者。

处置流程与药物剂量

  • 阿德西珠单抗组:静脉给予阿德西珠单抗8 mg/kg体重,单次给药。
  • 安慰剂组:静脉给予安慰剂,单次给药。
  • 随机分组按年龄(大于65岁 vs 小于65岁)、性别(男 vs 女)和心源性休克类型(急性心肌梗死 vs 其他病因)进行分层,采用区组随机化。

研究设计与关键结果

  • 研究类型:研究者发起、随机、双盲、安慰剂对照、多中心试验;在德国4所大学医院开展;2019年4月5日至2021年1月13日纳入150例患者,阿德西珠单抗组77例(51%),安慰剂组73例(49%);全部患者均接受了分配的治疗。
  • 主要终点(30天内无需心血管器官支持的天数,定义为无需血管升压药、正性肌力药或机械循环支持):阿德西珠单抗组12.37天(95%CI 9.80-14.94)vs 安慰剂组14.05天(95%CI 11.41-16.69),调整后平均差-1.69天(95%CI -5.37至2.00),p=0.37。
  • 严重不良事件:阿德西珠单抗组59例 vs 安慰剂组57例,OR 0.92(95%CI 0.43-1.98),p=0.83。
  • 30天死亡率:HR 0.99(95%CI 0.60-1.65),p=0.98;90天死亡率:HR 1.10(95%CI 0.68-1.77),p=0.71。
  • 安全性结局还包括治疗中出现严重不良事件、严重不良事件、不良事件、可疑非预期严重不良反应、研究药物相关死亡率和总死亡率。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照、多中心试验(研究者发起)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,阿德西珠单抗在急性心源性休克患者中耐受性良好,但未减少心血管器官支持需求,也未改善30天和90天生存率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Cardiogenic shock has a high mortality on optimal therapy. Adrenomedullin is released during cardiogenic shock and is involved in its pathophysiological processes. This study assessed treatment with the humanised, monoclonal, non-neutralising, adrenomedullin antibody adrecizumab, increasing circulating concentrations of adrenomedullin in cardiogenic shock.

METHODS: In this investigator-initiated, placebo-controlled, double-blind, multicentre, randomised trial (ACCOST-HH), patients were recruited from four university hospitals in Germany. Patients were eligible if they were 18 years old or older and hospitalised for cardiogenic shock within the last 48 h. Exclusion criteria were resuscitation for longer than 60 min and cardiogenic shock due to sustained ventricular tachycardia or bradycardia. Adult patients in cardiogenic shock were randomly assigned (1:1) to intravenous adrecizumab (8 mg/kg bodyweight) or placebo using an internet-based software. A block randomisation procedure was applied with stratification by age (older vs younger than 65 years), sex (male vs female), and type of underlying cardiogenic shock (acute myocardial infarction vs other entities). Investigators, patients, and medical staff involved in patient care were masked to group assignment. The primary endpoint was number of days up to day 30 without the need for cardiovascular organ support, defined as vasopressor therapy, inotropes, or mechanical circulatory support (or both) assessed in the intention-to-treat population. Safety outcomes included therapy-emergent serious adverse events, severe adverse events, adverse events, suspected unexpected serious adverse reactions, study drug-related mortality, and total mortality. The trial was registered at ClinicalTrials.gov, NCT03989531, and EudraCT, 2018-002824-17, and is now complete.

FINDINGS: Between April 5, 2019, and Jan 13, 2021, 150 patients were enrolled: 77 (51%) were randomly assigned to adrecizumab and 73 (49%) to placebo. All patients received the allocated treatment. The number of days without the need for cardiovascular organ support was not different between patients receiving adrecizumab or placebo (12·37 days [95% CI 9·80-14·94] vs 14·05 [11·41-16·69]; adjusted mean difference -1·69 days [-5·37 to 2·00]; p=0·37). Serious adverse events occurred in 59 patients receiving adrecizumab and in 57 receiving placebo (odds ratio 0·92 [95% CI 0·43-1·98]; p=0·83). Mortality was not different between groups at 30 days (hazard ratio 0·99 [95% CI 0·60-1·65]; p=0·98) or 90 days (1·10 [0·68-1·77]; p=0·71).

INTERPRETATION: Adrecizumab was well tolerated in patients with cardiogenic shock but did not reduce the need for cardiovascular organ support or improve survival at days 30 and 90.

FUNDING: Adrenomed AG and University Hospital of Hamburg.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Karakas M, Akin I, Burdelski C, et al. Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial. Lancet Respir Med. 2021. PMID: 34895483. doi:10.1016/S2213-2600(21)00439-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。